Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| https://osf.io/bcxv8 | Other Identifier | OSF |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Oslo University Hospital | OTHER |
| Linkoeping University | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
The main objective of the study is to test the hypothesis that opioid drug effects vary as a function of pre-drug affective state. Specifically, it is hypothesized that social stress induction enhances opioid drug wanting compared a non-stress control condition.
Healthy participants complete four experiment sessions in a placebo-controlled, double-blind, randomized repeated-measures psychopharmacological study. Participants completed four combinations of pre-drug state induction (social stress or no-stress) and drug (intravenous oxycodone or saline).
Temporary and reversible social stress is induced using the Repeatable Social Stress Test (ReSST) which enables repeated administrations of stress-inductions. Across four sessions participants experience two carefully tailored tasks to provoke the experience of social evaluative threat and two non-stressful control tasks.
After each state inductions, participants receive an injection of opioid drug or saline. After a drug absorption phase and viewing of a state reinstatement video designed to evoke a mild form of social evaluative threat participants perform a drug-self-administration test to determine the potency of a second dose.
Self-reported affect, mental and physiological state and drug effects are assessed throughout the session.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo_Control | Placebo Comparator | Control state induction: Participants answer simple questions about their color or music preferences in a hybrid (zoom-lab) session with a friendly experimenter (The Repeatable Social Stress Test (ReSST) control conditions). Drug administration: A sampling dose of intravenous (i.v.) saline administered over 15 seconds through a venous catheter after the state induction. 45 minutes later participants receive the second dose of saline (0-100% of the initial sampling dose) determined by a behavioral self-administration task. |
|
| Oxycodone_Control | Active Comparator | Control state induction: Participants answer simple questions about their color or music preferences in a hybrid (zoom-lab) session with a friendly experimenter. (The Repeatable Social Stress Test (ReSST) control conditions). Drug administration: A sampling dose of i.v. oxycodone administered over 15 seconds through a venous catheter after the state induction. 45 minutes later participants receive the second dose of oxycodone (0-100% of the initial sampling dose) determined by a behavioral self-administration task. |
|
| Placebo_Stress | Active Comparator | State induction: Stress The Repeatable Social Stress Test (ReSST) was used to induce psychosocial stress (mock job talk in stress session 1 and singing task in stress session 2). Drug administration: A sampling dose of i.v. saline administered over 15 seconds through a venous catheter after the state induction. 45 minutes later participants receive the second dose of saline (0-100% of the initial sampling dose) determined by a behavioral self-administration task. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oxycodone | Drug | 3.1mg oxycodone/70 kg body weight was administered as the main drug intervention. Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone. The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later. |
| Measure | Description | Time Frame |
|---|---|---|
| Amount of oxycodone self-administered in the behavioral drug wanting task relative to the first sampling dose (0-125%). | The number corresponds to the achieved cursor placement on a vertical electronic scale indicated desired effect intensity from second dose relative to the first (sampling) dose. Cursor placement depends on the amount of effort exerted (keyboard presses) and the task difficulty adapted to performance. The task ended abruptly after 2 minutes. | Single measure: final task result ~22 minutes after sampling dose |
| Self-report of oxycodone wanting relative to the first sampling dose (0-125 %) | Self-reported target effect intensity was indicated on a vertical scale at the onset of the behavioral drug wanting task before the effortful part of the task. Anchors visible to to participants were: "no effect/drug", "half the effect", "same effect", "a little stronger effect than the first drug dose". Numerically the scale anchors were 0-125 (VAS) where 100 corresponded to the "same effect". | Single measure: ~20 minutes after sampling dose |
| Self-reported drug wanting from "drug effects questionnaire". | Drug effects questionnaire (DEQ) take again item indicated on a 0-100 electronic Visual analogue scale (VAS) at two survey timepoints after the drug administration. Anchors were 'neutral' and 'very much'. Average rating was used. | From the drug administration until the start of the self-administration task (~15 minutes) |
| Measure | Description | Time Frame |
|---|---|---|
| Stress response 1: increase in self-reported stress to the primary stress induction and subsequent stress reinstatement (as compared to control tasks). | Change in ratings on the item "feeling stressed" measured on a 0-100 Visual Analogue Scale (VAS) The following items were collected to assess stress effects: anxious, self-conscious, embarrassed, vulnerable, happy, relaxed, irritable, confident, shaky, distressed, flushed face, heart palpitations, stomach discomfort, dizzy (to stress on a 0-100 VAS) and report this in the supplementary materials. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
All exclusion criteria required a 'yes' or 'no' response from participants. Participants were also asked to report any illnesses or medical conditions that were not covered by the questions in the clinical interview. Mental health and substance use were assessed during the clinical interview using the Mini-International Neuropsychiatric Interview (MINI). The interview required binary responses to questions regarding a wide range of psychological symptoms relevant for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) and ICD-10 (International Classification of Diseases) psychiatric disorders. Interviewers then used the pre-defined cut offs relevant to the severity of symptoms for each psychiatric disorder to assist the clinical judgement.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Siri Leknes, PhD | University of Oslo | Principal Investigator |
| Marie Eikemo, PhD | University of Oslo | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Oslo | Oslo | 0317 | Norway |
Not provided
| Label | URL |
|---|---|
| Time locked preregistration prior to data collection | View source |
| ID | Type | URL | Comment |
|---|---|---|---|
| Analytic Code | View IPD |
Anonymized information (non sensitive) will be shared on the Open Science Framework (OSF) at the time of publication.
The data will be released with the publication. The code, protocol, and supplementary materials have been released in the project repository.
none. For conditional access to health/sensitive data following publication contact the corresponding author (marie.eikemo@psykologi.uio.no) A data use agreement may also be required.
Not provided
| ID | Term |
|---|---|
| D015775 | Fractures, Stress |
| D009293 | Opioid-Related Disorders |
| ID | Term |
|---|---|
| D050723 | Fractures, Bone |
| D014947 | Wounds and Injuries |
| D000079524 | Narcotic-Related Disorders |
| D019966 | Substance-Related Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D010098 | Oxycodone |
| D012965 | Sodium Chloride |
| ID | Term |
|---|---|
| D003061 | Codeine |
| D009022 | Morphine Derivatives |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
Not provided
Not provided
Cross-over 2*2 design Drug (i.v. oxycodone/placebo) State induction (stress/control)
Not provided
Not provided
Experimenters, care providers (nurses/physicians) and participants were blinded to both the stress induction condition and the drug in all sessions.
| Oxycodone_Stress | Experimental | State induction: Stress ReSST was used to induce psychosocial stress (mock job talk in stress session 1 and singing task in stress session 2). Drug administration: A sampling dose of i.v. oxycodone administered over 15 seconds through a venous catheter after the state induction. 45 minutes later participants receive the second dose of oxycodone (0-100% of the initial sampling dose) determined by a behavioral self-administration task. |
|
|
| Placebo | Drug | Pure saline was administered as the placebo condition. Based on body weight, the study nurse/anesthetist adjusted the (unknown) content in two syringes by removing enough fluid to reach a volume that would result in a dose equivalent of 3.1mg/70kg (0,043 mg/ml pr kg) should the syringes contain oxycodone. The first dose was administered 5 minutes after the state induction task. The second dose was adjusted according to the performance on the self-administration task (but maximum 100% of the first dose) and administered 45 later. |
|
|
| Stress State Induction | Behavioral | ReSST is an in-house hybrid online-lab implementation of two stress induction paradigms based on the Trier Social stress test (TSST) and Iowa Social Singing Stress Test (I-SSST). The set-up was tailored to allow repeated stress induction without diminishing effects that allowed for an online experiment panel. Stress and control state inductions were administered every-other session. The singing version of the stress test was always administered last as it was deemed more stressful during piloting. |
|
|
| Control State Induction | Behavioral | Two different control tasks matched to the stress conditions on key parameters outlined in the protocol. |
|
|
| From the measure before state induction until the end of the state induction (~20 minutes). |
| Stress response 2: increase in physiological stress measured by heart rate (beats per minute: BMP) induced by the primary stress induction. | Heart rate change during the state induction compared to the time period before state induction. | Data from 20 minutes before to 20 minutes after the middle of the stress induction were used to estimate the heart rate increase |
| Stress response 3: change in endocrine stress response measured by cortisol induced by the primary stress induction. | Estimates of plasma cortisol levels changes from the baseline (2 blood samples) to the samples after the state induction (4 blood samples). | Throughout the experiment session (~3 hours, 6 samples) |
| Changes in positive and negative affect after the state manipulations (induction and reinstatement) and drug administrations | Select items from the PANAS based on pilot data. Baseline measures are collected several times before the state induction. Items were rated on a 0-100 Visual Analogue Scale (VAS). Negative affect (mood) items = "distressed", "anxious", "vulnerable", "irritable" Positive affect (mood) items = "good", "happy", "confident", "safe", "relaxed" Composite ratings from all measures collected throughout each session (k=11 measures) will be reported as descriptive information. | From immediately before to immediately after the state induction (~20 minutes) |
| Drug effects questionnaire (DEQ) | Drug effect, liking and disliking was measured using items from the Drug Effects Questionnaire (DEQ; 'Feel effect', 'Like effect', 'Dislike effect') measured on an electronic 0-100 VAS, anchors 'neutral' and 'very much'. | From the drug administration until the start of the self-administration task (~15 minutes) |
| Side effects | To assess the overall drug- and side effects, the following items were collected on a 0-100 electronic VAS: feeling high, blunted and dizzy. Additional items will be explored and reported where relevant and in the supplementary materials (feeling good, euphoric, indifferent, safe, dry mouth, nauseous, "not like myself"). | From the drug administration until the start of the self-administration task (~15 minutes) |
Project directory where study relevant documentation can be found and data will be uploaded. |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
| D000470 |
| Alkaloids |
| D006571 | Heterocyclic Compounds |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017670 | Sodium Compounds |